Is OPK Worth Buying as Valuation Meets Improving Business Trends?

OPKO Health, Inc. OPK combines a discounted forward sales multiple with improving operating trends, but the investment case remains balanced by ongoing losses and substantial clinical-development risk.

The shares look inexpensive against industry and sector benchmarks, while BioReference restructuring and pharmaceutical partnerships are improving the operating profile. Still, OPK has not established sustained profitability, and much of its longer-term upside depends on early-stage programs.

OPK's Valuation Is Cheap Relative to Key Benchmarks

OPK trades at 1.8X forward 12-month sales compared with 4.1X for the Zacks sub-industry and 2.2X for the broader Zacks sector. That discount gives the stock a lower valuation hurdle than its peer benchmarks.

The picture is less clear against OPK's own history. Its current multiple is above the five-year median of 1.6X, within a range of 0.7X to 2.6X. The valuation therefore looks inexpensive on a relative basis, but not unusually depressed versus the stock's historical norm.

Image Source: Zacks Investment Research

OPKO Health's Earnings Picture Is Improving but Still Red

Second-quarter 2026 loss narrowed to 1 cent per share from 19 cents a year earlier. Consolidated operating loss improved to $7 million from $60 million, helped by higher pharmaceutical revenues, lower Diagnostics costs and an $18.1 million gain tied to the Labcorp earnout.

The Zacks Consensus Estimate calls for a full-year 2026 loss of 22 cents per share versus a 30-cent loss in 2025. The improvement is meaningful, but profitability remains unfinished business as research and development spending rises and the company continues funding multiple clinical programs.

Image Source: Zacks Investment Research

OPK Has Multiple Catalysts but Heavy Clinical Risk

ModeX has five programs in clinical development, while MDX3001 is expected to begin first-in-human testing in late 2026 or early 2027. OPK-88006 has entered a Phase 1/2a study, and the OPK8801001 growth hormone receptor antagonist is targeted to reach clinical trials around the end of 2026.

Partnerships reduce some funding burden. Pfizer Inc. PFE commercializes NGENLA, while Regeneron Pharmaceuticals, Inc. REGN is funding development of selected assets under its ModeX collaboration. Even so, most of OPK's pipeline remains early stage, leaving efficacy, safety, regulatory and manufacturing execution as major uncertainties.

Image Source: Zacks Investment Research

OPKO Health's Balance Sheet Adds a Cushion

OPKO Health ended the second quarter with $314.4 million in cash, cash equivalents, marketable securities and restricted cash. Cumulative net cash used in operating activities improved to $62.8 million from $117.9 million a year earlier.

That liquidity provides room to support the pipeline while BioReference works toward a more efficient operating structure. The company still expects full-year research and development spending of $125-$135 million, so cash discipline remains important as clinical activity expands.

OPK's Mixed Style Scores Argue for Selectivity

The bottom line is that OPK's discounted relative valuation and improving operations support a more constructive view, but the remaining losses and early-stage pipeline keep the risk-reward profile mixed. The stock currently carries a Zacks Rank #3 (Hold), which fits a wait-and-see stance rather than a clear buying signal. You can see the complete list of today’s Zacks #1 (Strong Buy) Rank stocks here.

OPK has a Momentum Score of A, but its Value Score of F, Growth Score of C and VGM Score of C are less supportive. Zacks Style Scores are designed to complement the Zacks Rank, and the strongest combinations generally pair a Zacks Rank #1 or 2 (Buy) with Style Scores of A or B. For OPK, the current mix argues for selectivity while investors watch whether operating progress becomes durable profitability.

Research Chief Names "Single Best Pick to Double"

From thousands of stocks, 5 Zacks experts each have chosen their favorite to skyrocket +100% or more in months to come. From those 5, Director of Research Sheraz Mian hand-picks one to have the most explosive upside of all.

This company targets millennial and Gen Z audiences, generating nearly $1 billion in revenue last quarter alone. A recent pullback makes now an ideal time to jump aboard. Of course, all our elite picks aren’t winners but this one could far surpass earlier Zacks’ Stocks Set to Double like Nano-X Imaging which shot up +129.6% in little more than 9 months.

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

This article originally published on Zacks Investment Research (zacks.com).

Zacks Investment Research